Compare Twist Bioscience Corp (TWST) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wendys Co — how do they compare? Twist Bioscience Corp trades at $165.44 (market cap $10.08B), while Wendys Co trades at $6.16 (market cap $1.19B). The key difference: Twist Bioscience Corp is far larger — about 8.5× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Wendys Co for 77 Days on average.
| TWST | WEN | |
|---|---|---|
Market Cap | $10.08B | $1.19B |
Volume | 4,229,037 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $205.00 | $9.33 |
52-Week Low | $25.45 | $6.10 |
Typical Hold Time | 27 Days | 77 Days |
Enterprise Value | $10.01B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Wendy's stock (WEN) trades at $6.11, down 0.81% on the day, reflecting ongoing pressure from declining sales and a major franchisee bankruptcy. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a low P/E of 9.45 and strong ROE of 108.04%, but net income margins have fallen to 5.72%. Recent news highlights competitive struggles and store closures, though the company continues to beat earnings expectations.
The outlook remains cautious due to operational headwinds and high debt, but the current valuation may appeal to value investors. Risks include franchisee instability and intense competition. Analyst consensus is mixed with a $7.58 price target, suggesting limited upside from current levels amid uncertain recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
